With regard to the expression of the earlier activation marker CD69, we found an increase in the percentage of CD69+CD4+ T cells in the spleen following the combined treatment, and a tendency to a reduction of the cell percentage in the tumor (Figure 5a). This evidence concerns the gene CD69 and neoplasm.